Recent advances in nanomedicines for the treatment of ischemic stroke

Autor: Chao Li, Chen Jiang, Tao Sun
Jazyk: angličtina
Rok vydání: 2021
Předmět:
RGD
Arg-Gly-Asp

SHp
stroke homing peptide

GFs
growth factors

MSC
mesenchymal stem cell

Review
ICAM-1
intercellular adhesion molecule-1

PCMS
poly (chloromethylstyrene)

PSGL-1
P-selectin glycoprotein ligand-1

TNF-α
tumor necrosis factor-α

Blood‒brain barrier
0302 clinical medicine
NSCs
neural stem cells

Antithrombotic
LFA-1
lymphocyte function-associated antigen-1

Medicine
LHb
liposomal Hb

NMDAR
N-methyl-d-aspartate receptor

General Pharmacology
Toxicology and Pharmaceutics

e-PAM-R
arginine-poly-amidoamine ester

IL-6
interleukin-6

NOS
nitric oxide synthase

Stroke
PEG
poly-ethylene-glycol

0303 health sciences
PEG-PLA
poly (ethylene-glycol)-b-poly (lactide)

PLGA NPs
poly (l-lactide-co-glycolide) nanoparticles

HMGB1
high mobility group protein B1

PBCA
poly-butylcyanoacrylate

Nanomedicine
SUR1-TRPM4
sulfonylurea receptor 1-transient receptor potential melastatin-4

cRGD
cyclic Arg-Gly-Asp

030220 oncology & carcinogenesis
iNOS
inducible nitric oxide synthase

nNOS
neuron nitric oxide synthase

CsA
cyclosporine A

Thrombolytics
medicine.medical_specialty
TIA
transient ischemic attack

IL-1β
interleukin-1β

Side effect
SDF-1
stromal cell-derived factor-1

COX-1
cyclooxygenase-1

NGF
nerve growth factor

Ischemia
NF-κB
nuclear factor-κB

RM1-950
Neuroprotection
Ischemic cascade
Neuroprotectant
03 medical and health sciences
ROS
reactive oxygen species

BBB
blood‒brain barrier

SOD
superoxide dismutase

TEMPO
2
2
6
6-tetramethylpiperidine-1-oxyl

miRNAs
microRNAs

CXCR-4
C-X-C chemokine receptor type 4

cardiovascular diseases
Intensive care medicine
MCAO
middle cerebral artery occlusion

BCECs
brain capillary endothelial cells

NPs
nanoparticles

030304 developmental biology
business.industry
AEPO
asialo-erythropoietin

Therapeutic effect
Ce-NPs
ceria nanoparticles

PSD-95
postsynaptic density protein-95

medicine.disease
GPIIb/IIIa
glycoprotein IIb/IIIa

siRNA
small interfering RNA

Ischemic stroke
DAMPs
damage-associated molecular patterns

Reperfusion
RBCs
red blood cells

APOE
apolipoprotein E

MMPs
matrix metalloproteinases

Therapeutics. Pharmacology
CAT
catalase

business
RES
reticuloendothelial system

Hb
hemoglobin
Zdroj: Acta Pharmaceutica Sinica B, Vol 11, Iss 7, Pp 1767-1788 (2021)
Acta Pharmaceutica Sinica. B
ISSN: 2211-3835
Popis: Ischemic stroke is a cerebrovascular disease normally caused by interrupted blood supply to the brain. Ischemia would initiate the cascade reaction consisted of multiple biochemical events in the damaged areas of the brain, where the ischemic cascade eventually leads to cell death and brain infarction. Extensive researches focusing on different stages of the cascade reaction have been conducted with the aim of curing ischemic stroke. However, traditional treatment methods based on antithrombotic therapy and neuroprotective therapy are greatly limited for their poor safety and treatment efficacy. Nanomedicine provides new possibilities for treating stroke as they could improve the pharmacokinetic behavior of drugs in vivo, achieve effective drug accumulation at the target site, enhance the therapeutic effect and meanwhile reduce the side effect. In this review, we comprehensively describe the pathophysiology of stroke, traditional treatment strategies and emerging nanomedicines, summarize the barriers and methods for transporting nanomedicine to the lesions, and illustrate the latest progress of nanomedicine in treating ischemic stroke, with a view to providing a new feasible path for the treatment of cerebral ischemia.
Graphical abstract This review summarizes various nanomedicines, including liposomes, micelles, dendrimer, nanoparticles, and exosomes, which have been applied for the treatment of ischemic stroke. It especially focuses on their abilities to normalize various abnormalities at different phases of ischemic cascade, such as dissolving the clot and salvaging the penumbra.Image 1
Databáze: OpenAIRE